GlassScriptPhysician profile
Han Zhang
NPI 1659734929
$5,594.06
in general payments reported to CMS, 2019-2025
27 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $88.77 · 2021: $1,117 · 2022: $856 · 2023: $297 · 2024: $1,955 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,323 · Education: $26.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,323.06 |
| Education | $26.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,648.86 | 2020-2025 | Rinvoq, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $642.64 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Phathom Pharmaceuticals, INC. | $603.97 | 2024-2025 | Voquezna |
| Genzyme Corporation | $470.54 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $434.80 | 2024-2025 | Dupixent |
| Pfizer INC. | $246.15 | 2019-2025 | |
| Medtronic, INC. | $230.20 | 2022-2023 | Gi Genius |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.61 | 2022-2025 | Xifaxan |
| Olympus America INC. | $148.54 | 2022 | |
| Janssen Biotech, INC. | $125.10 | 2023-2025 | Stelara, Tremfya |
| E.R. Squibb & Sons, L.L.C. | $122.95 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $112.67 | 2024 | Dupixent |
| Merck Sharp & Dohme LLC | $85.05 | 2020-2024 | Dificid, Zinplava |
| Ardelyx, INC. | $66.66 | 2024-2025 | Ibsrela |
| Cook Medical LLC | $63.75 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $58.05 | 2023-2024 | Talicia |
| Davol INC. | $56.52 | 2023 | Phasix Mesh |
| Boston Scientific Corporation | $55.86 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Ferring Pharmaceuticals INC. | $34.47 | 2020-2025 | Rebyota |
| Lilly USA, LLC | $33.26 | 2025 | Omvoh |
| Celltrion USA INC. | $29.62 | 2025 | Vegzelma |
| Madrigal Pharmaceuticals | $28.58 | 2025 | Rezdiffra |
| Steris Corporation | $18.99 | 2025 | |
| Laborie Medical Technologies Corp. | $18.48 | 2024 | Alphaone |
| Aimmune Therapeutics, INC. | $17.58 | 2025 | Vowst |
| Evoke Pharma, INC. | $15.23 | 2024 | |
| Qol Medical, LLC | $14.93 | 2024 | Sucraid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Han Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.